CONFERENCE REPORTER
GLP-1 receptor agonists may offer an important new tool for psychiatric clinicians managing metabolic risks associated with antipsychotics, according to a literature review presented at the 2025 American Psychiatric Association Annual Meeting in Los Angeles, California.1,2
Amir Meftah, MD, a PGY-2 resident at One Brooklyn Health Interfaith Medical Center, and colleagues, conducted a systematic review of the literature to ascertain how GLP-1 receptor agonists may mitigate the cardiometabolic complications commonly associated with antipsychotic treatments.
For the review, Meftah et al identified 2 randomized clinical trials, 1 case report, and 1 retrospective study examining GLP-1 agonists in patients taking the antipsychotics clozapine or olanzapine. In 1 randomized controlled study, investigators…